Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 114 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Canakinumab, Placebo
Biological · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Charlestown, Massachusetts • Stony Brook, New York
Conditions
Alzheimer Disease
Interventions
PQ912, Placebo
Drug · Other
Lead sponsor
Vivoryon Therapeutics N.V.
Industry
Eligibility
50 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Chula Vista, California + 19 more
Conditions
Atypical Alzheimer's Disease, Logopenic Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA), Alzheimer Disease, Alzheimer Disease, Early Onset, Amnestic Disorder, Amnestic Symptoms, Amnestic Mild Cognitive Disorder
Interventions
F-18 AV 1451, C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Completed No phase listed Observational Accepts healthy volunteers

Implications for Management of PET Amyloid Classification Technology

NCT02778971
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
[18F]Flutemetamol
Drug
Lead sponsor
University of Utah
Other
Eligibility
45 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed No phase listed Observational Accepts healthy volunteers

Alzheimer's Disease Neuroimaging Initiative 3

NCT02854033
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Interventions
Not listed
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 90 Years
Enrollment
1,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 42 more
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Pioglitazone, Pioglitazone placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
65 Years to 83 Years
Enrollment
3,494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
34
States / cities
Phoenix, Arizona • Sun City, Arizona • Long Beach, California + 31 more
Recruiting Phase 2 Interventional Accepts healthy volunteers

Senicapoc in Alzheimer's Disease

NCT04804241
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Senicapoc, Placebo Tablet
Drug · Other
Lead sponsor
University of California, Davis
Other
Eligibility
55 Years to 85 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Sacramento, California • Walnut Creek, California
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
Interventions
Renew NCP-5
Device
Lead sponsor
Renew Research, LLC
Other
Eligibility
55 Years to 85 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
Recruiting No phase listed Observational Accepts healthy volunteers

Microbiome in Aging of Gut and Brain

NCT07799402
Conditions
Mild Cognitive Impairment, Alzheimer Disease (AD), Dementia
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Not applicable Interventional Accepts healthy volunteers

Closed-Loop Brain Stimulation as a Potential Intervention for Cognitive Decline

NCT05907343
Conditions
Mild Cognitive Impairment, Alzheimer Dementia (AD)
Interventions
Closed-loop TBS, Open-loop TBS
Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 90 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Austin, Texas
Conditions
Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild, Dementia Moderate, Dementia Alzheimers, Dementia of Alzheimer Type, AD
Interventions
Sensory Stimulation System (GS120) - Active
Device
Lead sponsor
Cognito Therapeutics, Inc.
Industry
Eligibility
50 Years to 92 Years
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Phoenix, Arizona • Sun City, Arizona • Anaheim, California + 48 more
Conditions
Mild Cognitive Impairment
Interventions
Octagam 10%
Biological
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Sacramento, California
Conditions
Mild Cognitive Impairment, Alzheimer Dementia
Interventions
CpG1018, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Alzheimer Disease
Interventions
ACU193, Placebo
Drug
Lead sponsor
Acumen Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Scottsdale, Arizona • Anaheim, California • Newport Beach, California + 14 more
Conditions
Mild Cognitive Impairment, Dementia, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Alzheimer Disease
Interventions
LY3002813, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
50 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Delray Beach, Florida • Orlando, Florida • The Villages, Florida + 3 more
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
Allopregnanolone injection (intravenous solution), Placebo injection (intravenous solution)
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Mild Traumatic Brain Injury, Moderate Traumatic Brain Injury, Mild Cognitive Impairment
Interventions
No Intervention is used for this study but all subjects will be asked to complete electroencephalogram (EEG) testing and an MRI scan., No intervention is used for this study but all subjects will be asked to complete a venous blood draw procedure and a lumbar puncture procedure.
Device · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
30 Years to 90 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

NCT02380573
Conditions
Mild Cognitive Impairment, MCI, Aging, Alzheimer's Disease, AD
Interventions
Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
45 Years to 89 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 2 Interventional Results available

Metformin in Amnestic Mild Cognitive Impairment

NCT00620191
Conditions
Mild Cognitive Impairment
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York